Evogene : Corporate Presentation

INVESTOR PRESENTATION

Ofer Haviv, President & CEO

June 2021

Forward Looking Statement

This presentation contains "forward-looking statements" relating to future events, and Evogene Ltd (the "Company"), may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting us that are considered "forward-looking statements" as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the "PSLRA") and other securities laws. Such forward-looking statements may be

identified by the use of such words as "believe", "expect", "anticipate", "should", "planned", "estimated", "intend" and "potential" or words of similar meaning. We are

using forward-looking statements in this presentation when we discuss our value drivers, commercialization efforts and timing, product development and launches, estimated market sizes and milestones, as well as the capabilities of Evogene's and our technology.

Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements, and trends in the future may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond our control, including, without limitation, those described in greater detail in Evogene's Annual Report on Form 20-F and in other information Evogene files and furnishes with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including those factors under the heading "Risk Factors".

Except as required by applicable securities laws, we disclaim any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of Evogene or the Company, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene or the Company.

The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of our products or services.

2

Agenda

Introduction

Fields of activity

Main subsidiaries

Summary

Annex I - Addressing the discovery and development challenges of life science-based product

Annex II - Financial Fundamentals

3

OUR VISION

DECODING BIOLOGY

Revolutionizing life-science based product discovery & development, utilizing cutting edge computational biology technologies.

4

Life-science product discovery & development challenges

Low probability of success with high cost and long time-to-market

Ag-chemicals		Pharmaceutical
Industry		Industry
Discovery and	CDER'S* annual novel
development costs	drug approvals:
of a new crop	2010-2019
protection product

Time to develop a new crop protection product

Source: Phillips McDougall, 2016

	1995	2000	2005-8	2010-15
Number of years between the first	8.3	9.1	9.8	11.3
synthesis and first sale of product
Source: Phillips McDougall, 2016

Source: U.S. Food and Drug Administration

Worldwide total pharmaceutical R&D spend in 2010-2024

*Center for Drug Evaluation and Research

Source: Evaluate Pharma May 2019

5